Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...
A Sarepta Therapeutics gene therapy that failed its confirmatory test has now converted its accelerated FDA approval into a traditional one, expanding use of the treatment to a wider group of Duchenne ...
On Tuesday, PepGen Inc. (NASDAQ:PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the ...
Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...
LEIDEN, THE NETHERLANDS, GAINESVILLE, FL, AND NEW YORK, NY, CA / ACCESS Newswire / October 16, 2025 / In a major advancement for Duchenne muscular dystrophy (DMD) research and patient care, a ...
Solid Biosciences ((SLDB)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Additional analyses from the givinostat clinical development program review observations on weight-based flexible dosing, characterization of thrombocytopenia, correlations between pharmacodynamic ...
African Americans with muscular dystrophy die 10 to 12 years younger than their white counterparts, according to research published in the Sept. 14 issue of Neurology, the medical journal of the ...
A retrospective cohort study found that, among 459 patients with DMD, constipation (32.5%) was the most common GI complication, followed by dysphagia (9.4%). Older age, lower body mass index, and use ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback